None
Quote | NervGen Pharma Corp (OTCMKTS:NGENF)
Last: | $2.09 |
---|---|
Change Percent: | -1.94% |
Open: | $2.1 |
Close: | $2.09 |
High: | $2.1 |
Low: | $2.09 |
Volume: | 1,197 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | NervGen Pharma Corp (OTCMKTS:NGENF)
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Message Board Posts | NervGen Pharma Corp (OTCMKTS:NGENF)
Subject | By | Source | When |
---|---|---|---|
This is the year for NGEN-F. | Schekin | investorshub | 04/10/2023 7:33:26 PM |
Yo GeoDan Check email on Seeking alpha, | Regis999 | investorshub | 08/02/2022 10:54:21 PM |
$NGENF NervGen Gets IndependentStudy Showing 65%RepairOfStrokeDamage+29%OnNews | geodan | investorshub | 07/29/2022 4:39:28 PM |
board of directors loaded with> fda/big pharma exec's,big | 81vette | investorshub | 07/29/2022 2:33:24 PM |
moved like a big board yesterday,$300k traded(14th of | 81vette | investorshub | 07/29/2022 1:20:07 PM |
News, Short Squeeze, Breakout and More Instantly...
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...